AttendMe Owl Logo
AttendMe
Evidence Evolution
OphthalmologyOphthalmology

How This Evidence Evolved

OCT in Retinal Disease

From fluorescein angiography to AI-enhanced optical coherence tomography

27.5

Timeline

Signal

Early observations and pilot data that first suggested a new direction

The 1991 OCT report described noninvasive cross-sectional biological imaging using low-coherence interferometry, with longitudinal and lateral resolution of a few micrometers. It demonstrated imaging in vitro in the peripapillary retina and coronary artery. A subsequent reproducibility study measured retinal nerve fiber layer thickness in 21 normal or glaucomatous eyes using approximately 10-micrometer-resolution OCT. Repeated measurements were reproducible, with better reproducibility using internal than external fixation. These sources distinguish the original laboratory demonstration from later clinical measurements.
Proof

Landmark RCTs and pivotal trials that established the evidence base

CATT and Protocol T assessed visual acuity as their primary outcome; OCT-based treatment guidance is a distinct question. A Cirrus–Stratus comparison found overall retinal nerve fiber layer discrimination AUCs of 0.953 versus 0.934 (P=.15), with better Cirrus performance on several early-glaucoma measures; this does not establish detection before visual-field loss. TREX-AMD individualized ranibizumab intervals after at least three monthly doses and resolution of clinical and spectral-domain OCT evidence of exudation.
Extension

Follow-up studies, subgroup analyses, and real-world validation

OCTA provides depth-resolved retinal and choroidal vascular images without injected contrast. It complements other imaging: motion-based scans cannot show vascular leakage and are vulnerable to artifacts and segmentation errors. The review illustrates greater penetration and less attenuation at 1050 nm than 840 nm, rather than a universal speed or performance claim. Separately, a deep-learning study trained on 14,884 three-dimensional OCT scans matched or exceeded expert referral-recommendation performance; this did not establish prediction of progression or treatment response.
Now

Current standard of care and ongoing research directions

In a newly diagnosed nAMD feasibility study, 14 of 40 eligible participants began Notal Vision home OCT scanning; 86.5% of scans were eligible for fluid quantification. ForeseeHome uses preferential hyperacuity perimetry, not OCT. Questions include visible-light resolution, widefield coverage, clinical-record integration, and whether ellipsoid-zone integrity, hyperreflective foci or fluid volume predict progression or treatment response. The referral AI result does not establish preventive treatment before clinical signs or a validated retinal digital twin.

Landmark Trials in This Story

Science (New York, N.Y.) 1991Landmark

Optical coherence tomography

Demonstration of in vitro OCT imaging

Science (New York, N.Y.)Technical development
Schuman OCT reproducibility1996

Reproducibility of nerve fiber layer thickness measurements using optical coherence tomography.

RNFL reproducibility over 1 month.

OphthalmologyProspective studyN=21
Protocol T2015Landmark

Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema

Mean visual-acuity change at one year

New England journal of medicineRCTN=660
Archives of ophthalmology (Chicago, Ill. : 1960) 2009

Comparison of glaucoma diagnostic Capabilities of Cirrus HD and Stratus optical coherence tomography

Sensitivity and specificity for glaucoma detection

Archives of ophthalmology (Chicago, Ill. : 1960)Diagnostic accuracy study
TREX-AMD2015

Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.

Visual acuity change at month 12: monthly 9.2 vs treat-and-extend 10.5 letters (P=0.60); mean injections 13.0 vs 10.1 (P<0.0001).

OphthalmologyRCTN=60
CATT2011

Ranibizumab and bevacizumab for neovascular age-related macular degeneration.

Visual acuity at 1 year: monthly bevacizumab +8.0 versus ranibizumab +8.5 letters; as-needed +5.9 versus +6.8. Serious systemic adverse events 24.1% versus 19.0% by drug (RR 1.29, 95% CI 1.01–1.66).

The New England journal of medicineRandomized single-blind noninferiority trialN=1,208
Nat Med 2018Landmark

Clinically applicable deep learning for diagnosis and referral in retinal disease

Referral recommendation performance relative to experts

Nat MedDiagnostic AI validation
Progress in retinal and eye research 2018

Optical coherence tomography angiography

Clinical utility of OCTA across retinal vascular diseases

Progress in retinal and eye researchReview
Ophthalmology. Retina 2024

Home OCT Imaging for Newly Diagnosed Neovascular Age-Related Macular Degeneration: A Feasibility Study.

14 of 40 eligible participants initiated scanning; 86.5% of 2304 scans were eligible for fluid quantification.

Ophthalmology. RetinaProspective observational home-OCT feasibility study in newly diagnosed nAMD
International ophthalmology clinics 2025

Use of Home Optical Coherence Tomography for Retinal Diseases.

Review of non-OCT home monitoring, including ForeseeHome, and home OCT for retinal disease.

International ophthalmology clinicsReview

Explore the evidence yourself

Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.

Frequently Asked Questions

How has OCT changed anti-VEGF treatment decisions?+
OCT can help guide individualized treatment intervals. In TREX-AMD, patients received monthly ranibizumab until clinical and OCT evidence of exudation resolved, then followed individualized intervals. At month 12, visual acuity improved by 9.2 letters with monthly treatment and 10.5 with treat-and-extend (P=0.60). Mean injections were 13.0 versus 10.1 (P<0.0001).
What is OCTA and does it replace fluorescein angiography?+
OCTA provides depth-resolved retinal and choroidal flow images without injected dye. Repeated B-scans detect motion from flowing red cells. It complements multimodal assessment of vascular occlusions, diabetic retinopathy, AMD and other disorders. The review describes faster acquisition than FA/ICGA, while emphasizing artifacts, segmentation errors and inability to assess leakage.
How is AI being applied to OCT imaging?+
A deep-learning study trained on 14,884 three-dimensional OCT scans matched or exceeded expert referral-recommendation performance across sight-threatening retinal diseases. Tissue segmentation supported transfer to a different imaging device. This result does not establish diagnostic accuracy for 50 separate conditions. Whether baseline OCT features predict progression or treatment response is a separate question.

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice. Clinical decisions should always be based on individual patient assessment, local guidelines, and professional judgement.

All data sourced from published, peer-reviewed articles and clinical practice guidelines.

Claims checked against cited sources: 10 November 2026